top of page

#ESMO21: Proffered Paper session - Genitourinary tumours, prostate

ESMO
9/18/21, 4:30 PM
Europe/Paris GMT+2

Description

#ESMO21 Sat, 18.09.2021

Time

13:30 - 14:50 LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study

Presentation Number

LBA24

Speakers

Neeraj Agarwal (Salt Lake City, United States of America)

Lecture Time

13:30 - 13:40

 

Invited Discussant LBA24

Speakers

Cora N. Sternberg (New York, United States of America)

Lecture Time

13:40 - 13:50

 

Q&A and live discussion

Lecture Time

13:50 - 13:55

 

577O - PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

Presentation Number

577O

Speakers

Shahneen K. Sandhu (Melbourne, VIC, Australia)

Lecture Time

13:55 - 14:05

 

Invited Discussant 577O

Speakers

Joaquin Mateo (Barcelona, Spain)

Lecture Time

14:05 - 14:15

 

Q&A and live discussion

Lecture Time

14:15 - 14:20

 

LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Presentation Number

LBA25

Speakers

Andrew J. Armstrong (Durham, United States of America)

Lecture Time

14:20 - 14:30

 

Invited Discussant LBA25

Speakers

Stephane M. Oudard (Paris, France)

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study, Invited Discussant LBA24, Q&A and live discussion, PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC), LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Inglês

Description

Speakers

Neeraj Agarwal, Cora N. Sternberg, Shahneen K. Sandhu, Joaquin Mateo, Andrew J. Armstrong, Stephane M. Oudard

Speakers

Link to the Event

Banner to the Event

#ESMO21: Proffered Paper session - Genitourinary tumours, prostate
Link to Event
Banner
Registro
bottom of page